Jonathan Miller interviews Rayetta Henderson, Senior Managing Scientist at Tox Strategies about her research and her testimony before the House Oversight Committee on the safety of hemp-derived CBD. If you have questions about the episode or ideas for Hemp related topics, email us at hemplegallyspeaking@fbtlaw.com.
Hemp Industry questions covered in the episode:
- What were the results of your toxicology studies on the safety of CBD isolate?
- How were thise results different from the studies championed by FDA concerning pharmaceutical-grade CBD found in the prescription drug Epidiolex?
- Why are studies of rodents applicable to the experience of humans?
- Have there been enough studies of CBD for FDA or Congress to be able to establish appropriate limits if CBD in dietary supplements and food/beverage?
- What counsel to you give to Congress as they go about the process of drafting legislation to regulate CBD?
